Brief topical sodium nitrite and its impact on the quality of life in patients with sickle leg ulcers

Joseph L. Connor Jr, MD\textsuperscript{a,b}, Joseph A. Sclafani, MD\textsuperscript{a,b}, Gregory J. Kato, MD\textsuperscript{c,d}, Matthew M. Hsieh, MD\textsuperscript{a,*}, Caterina P. Minniti, MD\textsuperscript{f}

Abstract
Cutaneous ulceration from sickle cell disease negatively impacts quality of life. Topical sodium nitrite has previously been shown to reduce the size of sickle leg ulcers. This study examined how topical sodium nitrite impacted the quality of life scores in patients with sickle leg ulcers.

We prospectively collected data in patients enrolled in a leg ulcer study (n = 17) or an allogeneic hematopoietic cell transplant study (nonulcer group, n = 15). Both groups completed a pretreatment Short Form-36 questionnaire; the ulcer group completed a second questionnaire after 4 weeks of topical sodium nitrite applications. Data were analyzed by age, sex, >50% area improvement postintervention, and sickle-related complications (vaso-occlusive crises, pulmonary hypertension, or avascular necrosis). Physical and mental component summary scores were analyzed with Student \textit{t} test.

Physical summary scores were lower than mental summary scores in all groups, indicating leg ulcers among other sickle related complications negatively impacted physical quality of life measures. After sodium nitrite use, physical summary scores improved in the leg ulcer group (34.5 ± 9.4 to 39 ± 10.3, \textit{P} = .03), and mental summary scores improved more in ulcerated patients ≤35 years old (40.7 ± 6.9 to 51.7 ± 9.7, \textit{P} = .01).

Brief topical sodium nitrite has the potential to improve quality of life, especially in younger individuals. Longer treatment duration and randomized-controlled trials are needed to confirm the efficacy of this topical therapy.

Abbreviations: AVN = avascular necrosis, COPD = chronic obstructive pulmonary disease, MCS = mental component summary, NO = nitric oxide, PCS = physical component summary, PHTN = pulmonary hypertension, QOL = quality of life, SCD = sickle cell disease, SD = standard deviation, SF-36 = medical outcomes study short-form 36-item survey, VOC = vaso-occlusive crises.

Keywords: leg ulcer, quality of life, sickle cell, sodium nitrite, wound

1. Introduction
Improvements in managing acute and chronic complications of sickle cell disease (SCD) have led to an increase in overall life expectancy for children living in high resource countries.\textsuperscript{[11]} As a result, the prevalence of chronic end organ damage, such as stroke, pulmonary hypertension (PHTN), renal injury, avascular necrosis of bone and joints (AVN), and cutaneous ulceration, is likely to increase as most children with SCD are living into adulthood.\textsuperscript{[6]}

Cutaneous ulcerations, or sickle cell ulcers, manifest mostly as distal leg ulcers around the malleoli, areas with thin skin and small amounts of subcutaneous fat.\textsuperscript{[3]} Sickle leg ulcers have a complex and partially understood etiology with a prevalence of 8% to 10% in North America.\textsuperscript{[4–6]} These ulcers heal as much as 16 times slower than venous stasis ulcers and have recurrence rates as high as 49% to 97%.\textsuperscript{[3,4,7,8]}

Topical sodium nitrite, providing nitrite anions, is a vasodilator in vivo by generating nitric oxide (NO) in tissues with lower oxygen tension and pH.\textsuperscript{[9]} This mechanism involves human hemoglobin and myoglobin as oxygen and pH dependent nitrite reductases, and sodium nitrite as the substrate for NO generation. When applied topically to the wound, sodium nitrite produces NO locally and promotes vasodilation. Additionally, NO may aid wound healing by stimulating extracellular matrix production, immune response modulation, and keratinocyte proliferation.\textsuperscript{[10]} We applied topical sodium nitrite to sickle leg ulcers in a phase I safety trial, and previously reported the primary outcome of wound healing after sodium nitrite application.\textsuperscript{[10]}

Sickle leg ulcers have a significant impact on patients’ morbidity and quality of life (QOL).\textsuperscript{[11–13]} These ulcers directly impact work capacity, mood, and sleep.\textsuperscript{[14,15]} The time required for daily ulcer care and provider appointments can result in decreased participation in school, work, or family activities. The
Clinical Trial Consortium for Comprehensive Sickle Cell Centers identified factors negatively associated with QOL.\[16\] Older age, specifically ages 30 to 50, vaso-occlusive crises (VOCs), asthma, AVN, and concurrent use of opioid and antidepressants, all reduced QOL scores. In other studies, sickle leg ulcers have had significant individual effects on the scores of the SF-36 survey, a generic measure of QOL.\[16,17\] However, studies had significant reduced QOL scores. In other studies, sickle leg ulcers have associations with asthma, AVN, and concurrent use of opioid and antidepressants, with small ulcers (clinicaltrials.gov, NCT01316796).[10] The accrual to a higher dose of sodium nitrite, from 0.5% to 2%, was based on the tolerability (lack of blood pressure changes, pain or edema after application, or methemoglobinemia <7%). The leg ulcer group received standard wound care and experimental topical sodium nitrite twice weekly for 4 weeks while continuing their sickle specific therapy (hydroxyurea or chronic transfusions). Those with small ulcers (<2.5 cm²), ulcers with infection, or ulcers suspected to be due to comorbid diabetes, venous stasis, or peripheral vascular disease were excluded.

The control, nonulcer group consisted of patients with SCD enrolled to receive allogeneic hematopoietic stem cell transplantation (clinicaltrials.gov, NCT00061568).[19,20]

Both groups completed a baseline Medical Outcomes Study 36-item Short-Form Survey (SF-36). A follow-up SF-36 was obtained in the leg ulcer group after sodium nitrite treatment. All surveys were scored using the algorithm set forth by the SF-36 Health Survey Manual.[21,22] The SF-36 embodies 8 scaled health dimensions including: physical function, physical role functioning, bodily pain, general health, vitality, social role functioning, emotional role functioning, and mental health. These 8 subscales were combined and reported here as physical and mental component summary (PCS and MCS) scores, as frequently reported in the literature. Subscale, PCS, and MCS scores are on a 100-point scale and have a normative mean of 50, with a standard deviation (SD) of 10, based on the 1998 National Survey of Functional Health Status.[23,24] The accrual of the study was based on the tolerability of sodium nitrite application, not on secondary QOL measures.

The data were analyzed by age, sex, >50% leg ulcer area healing over the 4 weeks of the intervention, occurrence of at least one VOC within 12 months preceding the treatment intervention, PHTN (confirmed by right heart catheterization), or AVN (documented by imaging). PCS and MCS scores were averaged for each subgroup. Statistical analyses of the mean summary scores were performed with paired or unpaired Student t tests with significance defined as P <.05. Statistical analyses were conducted using the statistical software StatPlus (version 6.0, AnalytSoft, Inc.).

### Methods

All patients provided written informed consent in accordance with the Declaration of Helsinki to clinical research protocols approved by the institutional review board of the National Heart, Lung, and Blood Institute. We prospectively collected QOL data in two groups of adults with SCD. The leg ulcer group was comprised of those with at least one cutaneous ulcer of at least 4 weeks duration, and an ulcer surface area between 2.5 and 100 cm², enrolling in a phase I trial using topical sodium nitrite (clinicaltrials.gov, NCT01316796).[10] The accrual to a higher dose of sodium nitrite, from 0.5% to 2%, was based on the tolerability (lack of blood pressure changes, pain or edema after application, or methemoglobinemia <7%). The leg ulcer group received standard wound care and experimental topical sodium nitrite twice weekly for 4 weeks while continuing their sickle specific therapy (hydroxyurea or chronic transfusions). Those with small ulcers (<2.5 cm²), ulcers with infection, or ulcers suspected to be due to comorbid diabetes, venous stasis, or peripheral vascular disease were excluded.

The control, nonulcer group consisted of patients with SCD enrolled to receive allogeneic hematopoietic stem cell transplantation (clinicaltrials.gov, NCT00061568).[19,20]

Both groups completed a baseline Medical Outcomes Study 36-item Short-Form Survey (SF-36). A follow-up SF-36 was obtained in the leg ulcer group after sodium nitrite treatment. All surveys were scored using the algorithm set forth by the SF-36 Health Survey Manual.[21,22] The SF-36 embodies 8 scaled health dimensions including: physical function, physical role functioning, bodily pain, general health, vitality, social role functioning, emotional role functioning, and mental health. These 8 subscales were combined and reported here as physical and mental component summary (PCS and MCS) scores, as frequently reported in the literature. Subscale, PCS, and MCS scores are on a 100-point scale and have a normative mean of 50, with a standard deviation (SD) of 10, based on the 1998 National Survey of Functional Health Status.[23,24] The accrual of the study was based on the tolerability of sodium nitrite application, not on secondary QOL measures.

The data were analyzed by age, sex, >50% leg ulcer area healing over the 4 weeks of the intervention, occurrence of at least one VOC within 12 months preceding the treatment intervention, PHTN (confirmed by right heart catheterization), or AVN (documented by imaging). PCS and MCS scores were averaged for each subgroup. Statistical analyses of the mean summary scores were performed with paired or unpaired Student t tests with significance defined as P <.05. Statistical analyses were conducted using the statistical software StatPlus (version 6.0, AnalytSoft, Inc.).

### Results

The entire cohort included a total of 32 participants, mean age of 35.9 ± 9.4 years (range 18–58). Seventeen participants were in the leg ulcer group (mean age 37 ± 10.2) and 15 in the control group (mean age 36.7 ± 8.6; P = .49). In the leg ulcer group, 9 patients were taking hydroxyurea and 3 patients were receiving chronic transfusions. In the control group, all were taking hydroxyurea for at least 2 months in preparation for planned hematopoietic cell transplant. Mean baseline PCS scores were lower than MCS scores (P = .03) and below the national normal mean of 50 (Tables 1 and 2).

Using the overall mean age, we further analyzed those >35 years and those ≤35 years at baseline. Individuals ≤35 years with leg ulcers had lower baseline MCS scores (40.7 ± 6.9, n = 8) than those in the same age group without a leg ulcer (51.1 ± 10.9, n = 9, P = .03) and those >35 years with a leg ulcer (50.8 ± 9.8, n = 9, P = .01). No other significant differences were noted in baseline summary scores between the corresponding leg ulcer subgroups.

We then focused our analyses on the leg ulcer group. The leg ulcers were present for >12 months in 7 of 17 individuals (41%). The mean leg ulcer area was 6.0 ± 3.4 cm² before topical sodium nitrite application and decreased to 3.3 ± 2.7 cm² after 4 weeks of therapeutic modalities over time, and identify treatments that would most benefit patients, or document the magnitude of such benefit.[18] We now report a secondary outcome on the impact of sickle leg ulcers on QOL summary scores before and after 4 weeks of topical sodium nitrite.

### Table 1

| Subgroups | n | Baseline PCS | Postintervention PCS | Change in PCS | Baseline MCS | Postintervention MCS | Change in MCS |
|-----------|---|--------------|----------------------|--------------|--------------|---------------------|--------------|
| Control group | All | 15 | 33.3 ± 12.9 | — | — | 51.0 ± 10.5 | — |
| | <35 y | 9 | 30.5 ± 12.9 | — | — | 51.1 ± 10.9 | — |
| | >35 y | 6 | 37.4 ± 13.3 | — | — | 50.9 ± 10.8 | — |
| | Male | 6 | 39.7 ± 11.7 | — | — | 48.8 ± 12.5 | — |
| | Female | 9 | 28.9 ± 12.4 | — | — | 52.5 ± 9.4 | — |
| Leg ulcer group | All | 17 | 34.5 ± 8.4 | 39.0 ± 10.3 | P = .03 | 46.9 ± 8 | 50.5 ± 8.9 | P = .13 |
| | <35 y | 8 | 33.3 ± 9.4 | 38.7 ± 8.8 | P = .09 | 40.7 ± 6.9 | 51.7 ± 9.7 | P = .01 |
| | >35 y | 9 | 35.6 ± 9.9 | 39.2 ± 12.1 | P = .23 | 50.8 ± 9.8 | 49.5 ± 8.7 | P = .73 |
| | Male | 8 | 38.3 ± 11.4 | 41.2 ± 13.3 | P = .11 | 47.8 ± 7.6 | 52.8 ± 8.6 | P = .26 |
| | Female | 9 | 31.2 ± 6.1 | 37.7 ± 2.6 | P = .12 | 44.5 ± 11.6 | 48.5 ± 9.3 | P = .36 |

MCS = mental component summary, PCS = physical component summary.

* A score of 50 reflects the national average, with higher scores reflecting better well-being or less symptomat.

Intervention was 4 weeks of topical sodium nitrite to sickle leg ulcer of at least 2.5 cm² or greater.
applications (P < .01) (Supplementary Materials, http://links.lww.com/MD/C627, http://links.lww.com/MD/C628). One patient achieved complete closure. No serious adverse events occurred. There were grade 1 adverse events that resolved spontaneously: asymptomatic decrease in diastolic blood pressure below 50 mm Hg, burning, pruritus, and oxygen desaturation to 91%. No patient discontinued the trial because of drug-related toxicities.

The overall PCS scores were higher postintervention (P = .03). Significant PCS score improvements were seen in those without PHTN (34.9 ± 9.8 to 40.3 ± 10.7, n = 14, P = .02) and without AVN (33.7 ± 9.3 to 40 ± 10.3, n = 13, P = .01).

In contrast to PCS, the overall MCS scores after the intervention were higher, but only as a trend (P = .13). None of the MCS scores in subgroup analyses showed a significant postintervention increase, except in those ≤35 years of age (40.7 ± 6.9 to 51.7 ± 9.7, n = 8, P = .01).

Improvements occurred in SF-36 health dimensions bodily pain (33.6 ± 6.8 to 44.5 ± 8.9, P < .01), vitality (43.8 ± 7.3 to 49.5 ± 9, P < .01), and social role functioning (39 ± 11.8 to 46.4 ± 9.9, P = .02).

### 4. Discussion

This study aimed to quantify perceived health-related QOL metrics in a small cohort of patients with SCD and chronic ulcers before and after topical sodium nitrite therapy. Overall, baseline SF-36 component summary scores showed that these lower extremity ulcers had the potential to negatively influence the individuals’ physical QOL (PCS), more than mental QOL (MCS). Previous studies have described similar outcomes in sickle cell patients and have correlated subjective pain at the ulcer site to impaired QOL. It was not surprising that PCS was lower than MCS scores in our leg ulcer cohort, since pain had a greater impact on PCS scores. It was also noteworthy to point out that leg ulcer pain may have contributed to pain crises, since the mean PCS score was lower in those with at least one VOC in the preceding 12 months (32.7 ± 10.9), compared to those without VOC (36.5 ± 7.7, P = .42).

Sickle leg ulcers may negatively impact MCS scores as well. The presence of ulceration in the ≤35 years subgroup was associated with lower MCS scores (40.7 ± 6.9), which were below an accepted threshold of clinical depression (MCS = 42).

Similarly, a sickle cell referral center in France examined a small cohort of patients with sickle leg ulcers and observed depression or mood changes in 85% of subjects. We hypothesized younger patients with ulcers may have felt more alienated from their peers, resulting in increased psychological stress, lower self-esteem, and/or depression, since they were still maturing psychosocially.

After serial applications of topical sodium nitrite, the leg ulcer group demonstrated improvements in PCS scores, possibly related to a reduction in pain, as previously reported. This improvement was observed especially in those with >50% ulcer healing (Table 2, P = .08), suggesting a possible relationship between ulcer size and QOL. Additionally, bodily pain improved the most among the SF-36 dimensions (Table 3).

Postintervention MCS scores increased modestly overall and in subgroup analyses, mostly in the ≤35 years subgroup. This may signify that younger patients have a greater likelihood of QOL improvements with topical sodium nitrite use, though further studies are needed.

The SF-36 questionnaire has previously been validated and applied to other chronic conditions. We compared our results to previously published PCS and MCS scores from patients with other diseases (Fig. 1). The PCS scores in patients with sickle leg ulcers were similar to patients with diabetic foot ulcers, receiving hemodialysis, or with chronic obstructive pulmonary disease, and lower than patients with operated lung.

### Table 2

**Quality of life scores before and after sodium nitrite application.**

| Subgroups                        | n  | Baseline PCS | Postintervention PCS | Change in PCS after intervention | Baseline MCS | Postintervention MCS | Change in MCS after intervention |
|----------------------------------|----|--------------|----------------------|----------------------------------|--------------|-----------------------|----------------------------------|
| Leg ulcer group >50% healing of ulcer area after intervention | 8  | 34.6 ± 9.5   | 41.3 ± 7             | P = .08                          | 46.3 ± 7.2   | 54.3 ± 8.4            | P = .01                          |
| <50% healing of ulcer area after intervention | 9  | 34.4 ± 9.9   | 36.9 ± 12.7          | P = .26                          | 45.8 ± 12.1  | 47.2 ± 8.5            | P = .64                          |
| No VOC in the past 12 mo         | 8  | 36.5 ± 7.7   | 38.9 ± 9.2           | P = .33                          | 49.5 ± 7.6   | 54.1 ± 5.7            | P = .14                          |
| 1 or more VOC in the past 12 mo  | 9  | 32.7 ± 10.9  | 39 ± 11.8            | P = .07                          | 43.0 ± 10.9  | 47.4 ± 10.4           | P = .4                           |
| No PHTN                          | 14 | 34.9 ± 9.8   | 40.3 ± 10.7          | P = .02                          | 45 ± 8.9     | 50.2 ± 9.3            | P = .14                          |
| History of PHTN                  | 3  | 32.6 ± 8.8   | 32.5 ± 5.8           | P = .98                          | 51.1 ± 14.1  | 52.3 ± 8.1            | P = .8                           |
| No AVN                           | 13 | 33.7 ± 9.3   | 40.1 ± 10.3          | P = .01                          | 46.6 ± 9.9   | 50.3 ± 8.7            | P = .31                          |
| History of AVN                   | 4  | 37.3 ± 10.8  | 35.7 ± 11.2          | P = .54                          | 44.2 ± 10.4  | 51.2 ± 10.9           | P = .25                          |

AVN = avascular necrosis, MCS = mental component summary, PHTN = pulmonary hypertension, VOC = vaso-occlusive crisis.

*A score of 50 reflects the national average, with higher scores reflecting better well-being or less symptom.

### Table 3

**Mean pre-post intervention scores by SF-36 health dimension.**

| Leg ulcer group’s mean SF-36 health dimension norm-based scores before and after topical sodium nitrite |
|------------------------------------------------------------------------------------------------|
| Health dimension                          | Baseline | Postintervention |
|-------------------------------------------|-----------|------------------|
| Physical functioning                      | 37        | 39.6             |
| Physical role functioning                 | 37.3      | 39.9             |
| Bodily pain                               | 33.6      | 44.5             |
| General health                            | 38.7      | 39.8             |
| Vitality                                  | 43.8      | 40.5             |
| Social role functioning                   | 39        | 46.4             |
| Emotional role functioning                | 40.1      | 43.7             |
| Mental health                             | 46.8      | 50.1             |

Note: The normative mean for the general population is 50 ± 10.
cancer or myocardial infarction. It was interesting to note that leg ulcers, which were perceived to be less medically urgent or require less medical attention, actually had a larger negative impact on QOL than some of the aforementioned diagnoses.

Our study was limited by small sample size, which likely reduced the generalizability to all patients with sickle leg ulcers. Additionally, longer than 4 weeks of treatment may be needed to confirm or observe greater improvement in QOL measurements, considering the recalcitrant nature of sickle leg ulcers.

5. Conclusion

Sickle leg ulcers contributed to the negative impact on health-related QOL scores, more than several medical illnesses that were perceived to require more care. Topical sodium nitrite has the potential to improve the broad physical component summary scores of QOL after 4 weeks of treatment. Longer treatment and randomized controlled trials would be needed to confirm the efficacy of sodium nitrite or other treatments.

Author contributions

Conceptualization: Gregory J. Kato, Caterina P. Minniti.

Data curation: Joseph L. Connor Jr, Gregory J. Kato, Caterina P. Minniti.

Formal analysis: Joseph L. Connor Jr, Joseph A. Sclafani.

Funding acquisition: Caterina P. Minniti, Matthew M. Hsieh.

Investigation: Gregory J. Kato, Caterina P. Minniti.

Methodology: Joseph L. Connor Jr, Joseph A. Sclafani, Matthew M. Hsieh.

Project administration: Caterina P. Minniti, Matthew M. Hsieh.

Software: Joseph L. Connor Jr, Joseph A. Sclafani.

Supervision: Caterina P. Minniti, Matthew M. Hsieh.

Writing—original draft: Joseph L. Connor Jr, Joseph A. Sclafani, Caterina P. Minniti, Matthew M. Hsieh.

Writing—review & editing: Joseph L. Connor Jr, Caterina P. Minniti, Matthew M. Hsieh.

Joseph L. Connor Jr orcid: 0000-0003-3797-6683.

References

[1] Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer 2013;60:1482–6.

[2] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease—life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–44.

[3] Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. Adv Skin Wound Care 2004;17:410–6.

[4] Akinyanju O, Akinsele L. Leg ulceration in sickle cell disease in Nigeria. Trop Geogr Med 1979;31:85–91.

[5] Koshy M, Erezah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989;74:1403–8.

[6] Minniti CP, Eckman J, Sebastiani P, et al. Leg ulcers in sickle cell disease. Am J Hematol 2010;85:831–3.

[7] Gordon S, Bui A. Human skin equivalent in the treatment of chronic leg ulcers in sickle cell disease patients. J Am Podiatr Med Assoc 2003;93:240–1.

[8] Senet P, Blas-Chatelain C, Levy P, et al. Factors predictive of leg-ulcer healing in sickle cell disease: a multicentre, prospective cohort study. Br J Dermatol 2017;177:206–11.

[9] Huang Z, Shiva S, Kim-Shapiro DB, et al. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest 2005;115:2099–107.

[10] Minniti CP, Gorbach AM, Xu D, et al. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. Lancet Haematol 2014;1:e95–103.

[11] Altman IA, Kleinfelder RE, Quigley JG, et al. A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease. Int Wound J 2016;13:1313–24.

[12] Hayek S, Dibo S, Baroud J, et al. Refractory sickle cell leg ulcer: is heparin sulphate a new hope? Int Wound J 2016;13:35–8.

[13] Serjeant GR. Leg ulceration in sickle cell anemia. Arch Intern Med 1974;133:690–4.

[14] Hareendran A, Bradbury A, Budd J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care 2005;14:53–7.

[15] Upton D, Andrews A. Sleep disruption in patients with chronic leg ulcers. J Wound Care 2013;22:389–390, 392, 394.

[16] Dampier C, Lelleau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol 2011;86:203–5.

[17] McClishe DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PSCES project. Health Qual Life Outcomes 2005;3:50.

[18] Meneses JV, Fortuna V, de Souza ES, et al. Autologous stem cell-based therapy for sickle cell leg ulcer: a pilot study. Br J Haematol 2016;175:949–55.

[19] Hsieh MM, Fitzhugh CD, Westzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014;312:48–56.

[20] Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309–17.

[21] Ware JE, Kosinski M, Dewey JE, et al. SF-36 Health Survey: Manual and Interpretation Guide. Quality Metric, Inc.; 2000.

[22] Ware JE, New England Medical Center Health Institute, New England Medical Center Medical Research Center; 1997.

[23] Sclafani JA, Akuthota V. Integration of patient-reported health-related quality of life measures for low back pain into clinical practice: an
overview of validated, frequently utilized instruments. Curr Phys Med Rehabil Rep 2016;4:12–8.

[24] Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130–9.

[25] Anie KA, Steptoe A, Bevan DH. Sickle cell disease: pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol 2002;7:331–44.

[26] Rallas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 2006;4:39.

[27] Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer 2012;59:377–85.

[28] Rijken M, van Kerkhof M, Dekker J, et al. Comorbidity of chronic diseases. Qual Life Res 2005;14:45–55.

[29] Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.1. Health Qual Life Outcomes 2007;5:54–154.

[30] Halabi-Tawil M, Lionnet F, Girot R, et al. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol 2008;158:339–44.

[31] Silveira E, Taft C, Sundh V, et al. Performance of the SF-36 Health Survey in screening for depressive and anxiety disorders in an elderly female Swedish population. Qual Life Res 2005;14:1263–74.

[32] Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004;13:283–98.

[33] McHorney CA, Ware JE, Lu JFR, et al. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40–66.

[34] Franks PJ, McCallagh L, Moffatt CJ. Assessing quality of life in patients with chronic leg ulceration using the Medical Outcomes Short Form-36 questionnaire. Ostomy Wound Manage 2003;49:26–37.

[35] Czyzewski L, Sanko-Resmer J, Wyzgal J, et al. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant 2014;19:576–85.

[36] HajGhanbari B, Holsti L, Road JD, et al. Pain in people with chronic obstructive pulmonary disease (COPD). Respir Med 2012;106:998–1005.

[37] Myrdal G, Valtysdottir S, Lambe M, et al. Quality of life following lung cancer surgery. Thorax 2003;58:184–7.

[38] Müller-Nordhorn J, Roll S, Willich S. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease. Heart 2004;90:523–7.